Copyright
©The Author(s) 2023.
World J Hepatol. May 27, 2023; 15(5): 585-608
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.585
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.585
For adult patients | Treatment |
Immune-active CHB (HBeAg negative or positive) | Antiviral therapy as PEG-IFN, tenofovir, or entecavir to decrease the risk of liver complications |
Immune-tolerant CHB | Against antiviral therapy. Continuous monitoring of ALT levels at least every 6 mo for potential transition to immune-active or inactive CHB |
Immune-active CHB HBeAg-negative | Indefinite antiviral therapy, unless there is a strong indication for treatment withdrawal |
Compensated cirrhosis with low levels of viremia (< 2000 IU/mL) | Antiviral therapy to reduce the risk of decompensation, regardless of ALT level |
Decompensated cirrhosis with positive HBsAg | Indefinite antiviral therapy, irrespective of the level of HBV DNA, ALT, or HBeAg status to decrease risk of worsening the condition |
HBeAg-positive CHB without cirrhosis seroconvert to anti-HBe on NA therapy | Discontinue NAs after a period of treatment consolidation |
HBeAg-positive CHB with cirrhosis seroconvert to anti-HBe on therapy | Indefinite antiviral therapy unless there is a strong indication for treatment withdrawal |
For children (2 to < than 18 years) | Treatment |
HBeAg positive with elevated ALT and HBV DNA levels | Antiviral therapy (IFN-α, PEG-IFN, and NAs) aiming for achieving sustained HBeAg seroconversion. PEG-IFN-α is recommended for use compared to NAs due to absence of viral resistance and finite duration of treatment |
HBeAg-positive with persistently normal ALT, regardless of HBV DNA level | Against antiviral therapy |
- Citation: Salama II, Sami SM, Salama SI, Abdel-Latif GA, Shaaban FA, Fouad WA, Abdelmohsen AM, Raslan HM. Current and novel modalities for management of chronic hepatitis B infection. World J Hepatol 2023; 15(5): 585-608
- URL: https://www.wjgnet.com/1948-5182/full/v15/i5/585.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i5.585